Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline

Excerpt

Since the identification of germline mutations in BRCA1 and BRCA2, there has been continuous evolution in the identification of additional susceptibility germline mutations that increase risk for breast cancer and other malignancies. With the application of next-generation sequencing, not only has the pace of discovery accelerated in the past decade but this has occurred at a considerable reduction in cost. Thus, physicians are now faced with the challenge of how to appropriately integrate this rapidly expanding information into daily practice. Although existing guidelines and recommendations have focused on the management of future cancer risk associated with germline mutations as well as surveillance and prevention strategies, guidance on the management of patients with germline mutations and newly diagnosed breast cancer has not kept up with the rapid pace of discovery. …